Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | PRKCB | P05771 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3462061 | 1.00 | MAPK1 (0.50) | MAPK1DRD2DRD3APPPRKCB | |
| SCHEMBL22117940 | 1.00 | MAPK1 (0.50) | MAPK1DRD2DRD3APPPRKCB | |
| SCHEMBL3066733 | 0.86 | MAPK1 (0.46) | MAPK1DRD2DRD3APPPRKCB | |
| SCHEMBL3066729 | 0.86 | MAPK1 (0.46) | MAPK1DRD2DRD3APPPRKCB | |
| SCHEMBL3081193 | 0.86 | MAPK1 (0.46) | MAPK1DRD2DRD3APPPRKCB | |
| SCHEMBL13662624 | 0.86 | P2RX7 (0.42) | MAPK1DRD2DRD3PRKCBSMN1; SMN2 | |
| SCHEMBL1393516 | 0.84 | ALOX15 (0.40) | MAPK1DRD2DRD3SMN1; SMN2PTGDR2 | |
| SCHEMBL18420898 | 0.80 | KCNK3 (0.41) | MAPK1DRD2DRD3HSD11B1PTGDR2 | |
| SCHEMBL28117625 | 0.80 | KCNK3 (0.41) | MAPK1DRD2DRD3HSD11B1PTGDR2 | |
| SCHEMBL13733481 | 0.80 | HSD17B10 (0.37) | DRD2DRD3SMN1; SMN2PTGDR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873283-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-11713315-B2 | 5 to 7 membered heterocyclic amides as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-01 | — | — | US | disclosed |
| EP-3837010-B1 | 5 TO 7 MEMBERED HETEROCYCLIC AMIDES AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-3837253-B1 | PROCESS FOR PREPARING JAK INHIBITORS AND INTERMEDIATES THEREOF | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230002321-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORP (US) | 2023-01-05 | — | — | US | disclosed |
| EP-3897636-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Celgene Corporation (US) | 2021-10-27 | — | — | EP | disclosed |
| US-11149007-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2021-10-19 | — | — | US | disclosed |
| EP-3837253-A1 | PROCESS FOR PREPARING JAK INHIBITORS AND INTERMEDIATES THEREOF | Theravance Biopharma R&D IP, LLC (US) | 2021-06-23 | — | — | EP | disclosed |
| CN-112703037-A | 5-to 7-membered heterocyclic amides as JAK inhibitors | 施万生物制药研发IP有限责任公司 | 2021-04-23 | — | — | CN | disclosed |
| CN-112638902-A | Methods for preparing JAK inhibitors and intermediates thereof | 施万生物制药研发IP有限责任公司 | 2021-04-09 | — | — | CN | disclosed |
| US-20210024517-A1 | 5 TO 7 MEMBERED HETEROCYCLIC AMIDES AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-01-28 | — | — | US | disclosed |
| US-10844057-B2 | Process for preparing JAK inhibitors and intermediates thereof | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-11-24 | — | — | US | disclosed |
| US-10836763-B2 | 5 to 7 membered heterocyclic amides as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-11-17 | — | — | US | disclosed |
| WO-2020132014-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORPORATION (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20200199073-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2020-06-25 | — | — | US | disclosed |
| US-20200071325-A1 | 5 TO 7 MEMBERED HETEROCYCLIC AMIDES AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-03-05 | — | — | US | disclosed |
| US-20200071324-A1 | PROCESS FOR PREPARING JAK INHIBITORS AND INTERMEDIATES THEREOF | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844057-B2 | Process for preparing JAK inhibitors and intermediates thereof | JAK2, JAK1, JAK3 | MAPK1 182/4885DRD2 4169/4885DRD3 4011/4885 |
| US-20210024517-A1 | 5 TO 7 MEMBERED HETEROCYCLIC AMIDES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | MAPK1 96/4885DRD2 4229/4885DRD3 4437/4885 |
| US-20230002321-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | AR, NR5A2, ESRRA | MAPK1 3979/4885DRD2 294/4885DRD3 358/4885 |
| US-11873283-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | AR, NR5A2, ESRRA | MAPK1 3979/4885DRD2 294/4885DRD3 358/4885 |
| US-10836763-B2 | 5 to 7 membered heterocyclic amides as JAK inhibitors | JAK1, JAK2, JAK3 | MAPK1 96/4885DRD2 4229/4885DRD3 4437/4885 |
| US-20200071324-A1 | PROCESS FOR PREPARING JAK INHIBITORS AND INTERMEDIATES THEREOF | JAK2, JAK1, JAK3 | MAPK1 182/4885DRD2 4169/4885DRD3 4011/4885 |
| US-11713315-B2 | 5 to 7 membered heterocyclic amides as JAK inhibitors | JAK1, JAK2, JAK3 | MAPK1 96/4885DRD2 4229/4885DRD3 4437/4885 |
| US-11149007-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | AR, NR5A2, ESRRA | MAPK1 3979/4885DRD2 294/4885DRD3 358/4885 |
| US-20200199073-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | AR, NR5A2, ESRRA | MAPK1 3979/4885DRD2 294/4885DRD3 358/4885 |
| US-20200071325-A1 | 5 TO 7 MEMBERED HETEROCYCLIC AMIDES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | MAPK1 96/4885DRD2 4229/4885DRD3 4437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.